TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05412030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFX3772
Description: AFX3772 administered intramuscularly 4 times within 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFX3772
Description: AFX3772 administered intramuscularly 4 times within 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFX3772
Description: AFX3772 administered intramuscularly 4 times within 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: PCV13 administered intramuscularly 4 times within 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 20
Description: PCV 20 administered intramuscularly 4 times within 12 months
Study: NCT05032755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPECTRUM NRC 102/103 investigational cigarettes
Description: Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPECTRUM NRC 600/601 investigational cigarettes
Description: Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
Study: NCT06094205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainGate Neural Interface System
Description: Placement of the BrainGate2 sensor(s) into the speech-related cortex
Study: NCT05882318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin Peripheral Neurostimulator System
Description: The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin Peripheral Neurostimulator System
Description: The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
Study: NCT04077281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Coordinated care
Description: * Clinical Pharmacology \& Toxicology consult~* CPT team completes detailed circle of care communication~* Telemedicine followup by CPT team (approximately 48 hrs post-discharge \& 1 week to1 month post-discharge)
Study: NCT05889390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncotherm EHY-2030
Description: Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: weekly paclitaxel for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: weekly paclitaxel for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: added to weekly paclitaxel if patient has triple-negative breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: added to weekly paclitaxel if patient has triple-negative breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin
Description: according to the AC protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/Doxorubicin
Description: according to the AC protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast cancer removal surgery
Description: Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast cancer removal surgery
Description: Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
Study: NCT04713514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: 400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
Study: NCT06384430

Intervention type: DIAGNOSTIC_TEST
Intervention: Shoulder functional tests and ultrasound
Description: On the day of the study, demographic data will be collected from patients with a clinical diagnosis of impingement and who agree to participate in the study, then DASH and Constant Murley scores will be calculated and subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio will be calculated on ultrasound.
Study: NCT05495711

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human umbilical cord mesenchymal stem cell complex collagen
Description: 1 \* 10\^7 cells (2ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell complex collagen
Description: 1 \* 10\^7 cells (2ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine injection
Description: intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
Study: NCT06356142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palmar Cooling
Description: Palmar cooling device will be utilized for 2 minutes during rest breaks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Palmar Cooling
Description: Placebo Palmar cooling device will be utilized for 2 minutes during rest breaks
Study: NCT06030089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: 4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital status determination
Description: Survival situation 12 months after start of treament

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toxicity assessments
Description: Toxicity events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine combination
Description: Response to treatment
Study: NCT06675136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05939947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALE.F02
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Study: NCT06675136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT06674551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block and Axillary nerve block
Description: A linear ultrasound probe will be placed in a sagittal plane at the superior medial border of the scapula. The probe will be moved laterally and then placed parallel to the scapular spine. when the needle tip contacts the bone just medial to the spinoglenoid notch and after confirmation of absence of vascular structure by color Doppler, 10 ml of 0.5% bupivacaine will be injected with aspiration every 3 ml to avoid intravascular injection and the spread of the local anaesthetic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene Nerve Block
Description: The ultrasound probe will be placed in the supraclavicular fossa in a transverse orientation, aimed caudad into the thoracic cavity, to visualize the brachial plexus near the subclavian artery. Once identified, the plexus will be followed cephalad where it is found within the brachial plexus fascial sheath in the interscalene groove.
Study: NCT05893732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Description: Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-Intensity Laser Therapy (Sham HILT)
Description: Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
Study: NCT06611696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan, prednisolone and rituximab
Description: Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and rituximab
Description: Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.
Study: NCT05907980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE12
Description: ROSE12 as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE12
Description: ROSE12 as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE12
Description: ROSE12 as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE12
Description: ROSE12 as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE12
Description: ROSE12 as a IV infusion
Study: NCT04228276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
Study: NCT05877547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection of matching placebo
Study: NCT05320796

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: upper endoscopy
Description: A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: upper endoscopy
Description: A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
Study: NCT05907980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab as a IV infusion
Study: NCT05272449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep apnea diagnosis
Description: Split-night
Study: NCT03816319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UAE Inhibitor TAK-243
Description: Given IV
Study: NCT04843371

Intervention type: DIAGNOSTIC_TEST
Intervention: Photoplethysmography
Description: Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
Study: NCT04752189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Replicating Effective Programs (Enhanced REP)
Description: Enhanced REP includes 1. a tailored MMH curriculum, 2. tailored training, and 3. ongoing provider consultation or facilitation to support implementation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard implementation
Description: The standard implementation of the Michigan Model for Health is consistent with Standard REP and includes the curriculum materials, standard training, and as-needed technical assistance.
Study: NCT05463003

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
Study: NCT06091332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch flake
Description: The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
Study: NCT05303519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safusidenib
Description: safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safusidenib
Description: safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safusidenib
Description: safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
Study: NCT05067907

Intervention type: PROCEDURE
Intervention: Early physiotherapy
Description: Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration.
Study: NCT04766710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based ART delivery (CAD)
Description: The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART multi-month dispensing (MMD)
Description: The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.